Next Generation News and Research

RSS

HIV vaccine study marks breakthrough in targeting broad immune responses

A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus.

15 May 2025

Next generation module improves flow process automation

Vapourtec has recently unveiled their Reaction Controller and Datalogger Module which improves the automation of flow chemistry experiments by enabling automated control and logging when using third-party pumps, recirculators, flow meters, sensors and balances.

14 May 2025

New insights into HIV-1 capsid disruption open doors for novel therapies

Announcing a new publication for Acta Materia Medica journal. The HIV-1 capsid protein (CA) plays a crucial role in viral replication by orchestrating nuclear entry through interactions with host nuclear pore complexes (NPCs).

13 May 2025

Researchers unlock new paths toward treating stress-related psychiatric disorders

In a comprehensive Genomic Psychiatry review article published today, researchers from the University of Rochester Medical Center have synthesized decades of research on stress hormone systems in primate brains, potentially unlocking new paths toward treating stress-related psychiatric disorders.

13 May 2025

HER3 reemerges as a key driver of cancer progression and therapy resistance

A new publication shines a spotlight on HER3, a long-overlooked member of the ErbB receptor family, revealing its critical role in cancer progression and resistance to therapy.

12 May 2025

Tirzepatide outperforms semaglutide in weight loss clinical trial

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the injectable drugs.

12 May 2025

Breakthrough discovery offers hope for treating neurodegenerative diseases

Researchers have discovered how to block cells dying, in a finding that could lead to new treatments for neurodegenerative conditions like Parkinson's and Alzheimer's.

12 May 2025

PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced Barbara Duncan has joined its Board as Chair, and Stephen Dilly as Non-Executive Director.

From PhoreMost 12 May 2025

Maternal health during pregnancy linked to higher blood pressure in children

Children born to mothers with obesity, gestational diabetes mellitus or a hypertensive disorder of pregnancy have higher systolic and diastolic blood pressure than children born to mothers without these risk factors, according to a new USC study.

8 May 2025

Next-generation "armored" CAR T cell therapy shows promising results in lymphoma patients

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies.

8 May 2025

Teen drivers face higher risks in older vehicles

Motor vehicle crashes are the leading cause of death for U.S. teens. Newer vehicles and driver assistance technologies show promise in reducing crashes and injury severities.

7 May 2025

Precision medicine approach improves treatment for soft tissue sarcomas

A study conducted by researchers from the Agency for Science, Technology and Research (A*STAR), National Cancer Centre Singapore (NCCS) and National University of Singapore (NUS), in collaboration with biotech company, KYAN Technologies, has demonstrated that a precision medicine approach improves treatment selection for patients with soft tissue sarcomas (STS) in a clinical setting.

7 May 2025

Scientists engineer new drug candidate to fight deadly mycobacterial infection

In a classic example of scientific problem solving, scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) and colleagues have published a paper introducing a promising new drug candidate they engineered to target a deadly and emerging infection.

6 May 2025

New rifamycin drugs fight antibiotic-resistant lung infections more effectively

Researchers have developed next-generation rifamycin analogs that effectively kill both replicating and nonreplicating Mycobacterium abscessus while minimizing drug-drug interactions. Lead candidates UMN-120 and UMN-121 showed superior efficacy to current treatments in mouse models and retained potency against M. tuberculosis.

5 May 2025

Heart Failure 2025 congress set for May in Belgrade, Serbia

Heart Failure 2025, the world's leading congress on heart failure, will take place from 17 to 20 May in Belgrade, Serbia.

5 May 2025

Trump team’s $500 million bet on old vaccine technology puzzles scientists

The Trump administration's unprecedented $500 million grant for a broadly protective flu shot has confounded vaccine and pandemic preparedness experts, who said the project was in early stages, relied on old technology, and was just one of more than 200 such efforts.

5 May 2025

The Surgeon-Scientist Pioneering Regenerative Engineering

In this interview, Sir Prof. Cato T. Laurencin, the 2025 Coulter Lecturer, discusses how he is addressing today’s medical challenges using the technology of the future.

From Pittcon 5 May 2025

Gene-edited immune cells show promise against advanced GI cancers

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.

3 May 2025

HHS and NIH announce the development of next-generation, universal vaccine platform

Colorized transmission electron micrograph of influenza A/H1N1 virus particles. The U.S. Department of Health and Human Services (HHS) and the National Institutes for Health (NIH) today announced the development of the next-generation, universal vaccine platform, Generation Gold Standard, using a beta-propiolactone (BPL)-inactivated, whole-virus platform.

1 May 2025

Urgent action needed to close gaps in global pandemic preparedness

The Global Virus Network (GVN) is highly concerned that the world is unprepared for the next pandemic and has not incorporated the lessons learned from COVID-19.

30 Apr 2025